Forma Therapeutics, Inc.

Valo Health, Inc.

H. Lundbeck A/s

Valo Early Discovery, Inc.

Lundbeck, H., A/s

Hongbin Li

Shawn E R Schiller

Steven Gregory Mischke

David R Lancia, Jr

Kenneth W Bair

Matthew W Martin

Justin Andrew Caravella

Angela V West

Jennifer R Downing

Anna M Ericsson

David S Millan

Wei Lu

David James Richard

David Joseph Guerin

Tatiana Shelekhin

Torsten Herbertz

Bradford Graves

Mark Joseph Tebbe

James Loch

Pui Yee Ng

Zhongguo Wang

Stephanos Ioannidis

Jun Yuan

Mary-Margaret Zablocki

David Juergen Wustrow

Jianmin Mao

Alan J Hutchison

Rajagopal Bakthavatchalam

He Zhao

Kevin J Hodgetts

Alex J Buckmelter

Scott Capitosti

Qin Guo

Shawn Er Schiller

Scott M Capitosti

David R Lancia

Shawn ER Schiller

David R Lancia Jr

Mark J Tebbe

Jr David R Lancia

David J Wustrow

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Inhibiting CREB binding protein (CBP)

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.

Inhibiting cyclic AMP-responsive element-binding protein (CREB)

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments. The present disclosure provides compounds of Formula (I).

Inhibiting deubiquitinase USP25 and USP28

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

Carboxamides as ubiquitin-specific protease inhibitors

The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.

Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors

Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors

The disclosure relates to USP30 Inhibitor Compounds I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same. (I) 

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R, R, R, R, R, R, R, X, and n are described herein. 

Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below: 

Compounds and compositions for inhibition of FASN

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: where R, R, R, R, R, R, R, R, X, m, and n are described herein.

Thienopyridine carboxamides as ubiquitin-specific protease inhibitors

Growing community of inventors

Madison, CT, United States of America

Hongbin Li